Efficacy and safety of Ginkgo biloba extract EGb 761® in mild cognitive impairment with neuropsychiatric symptoms: a randomized, placebo-controlled, double-blind, multi-center trial

Objective The study was conducted to explore the effects of EGb 761® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) on neuropsychiatric symptoms (NPS) and cognition in patients with mild cognitive impairment (MCI). Methods One hundred and sixty patients with MCI who scored at least 6 on...

Full description

Saved in:
Bibliographic Details
Published in:International journal of geriatric psychiatry 2014-10, Vol.29 (10), p.1087-1095
Main Authors: Gavrilova, S. I., Preuss, U. W., Wong, J. W. M., Hoerr, R., Kaschel, R., Bachinskaya, N.
Format: Article
Language:eng ; rus
Subjects:
Aged
Aged, 80 and over
Anxiety - drug therapy
behavior
Clinical trials
Cognitive ability
Cognitive Dysfunction - drug therapy
Depressive Disorder - drug therapy
Double-Blind Method
EGb 761
executive function
Female
Geriatric psychiatry
Ginkgo biloba
Herbs
Humans
Male
Middle Aged
mild cognitive impairment
neuropsychiatric symptoms
Neuropsychological Tests
Phytotherapy - methods
Placebo effect
Plant Extracts - adverse effects
Plant Extracts - therapeutic use
Standard deviation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The study was conducted to explore the effects of EGb 761® (Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany) on neuropsychiatric symptoms (NPS) and cognition in patients with mild cognitive impairment (MCI). Methods One hundred and sixty patients with MCI who scored at least 6 on the 12‐item Neuropsychiatric Inventory (NPI) were enrolled in this double‐blind, multi‐center trial and randomized to receive 240 mg EGb 761 daily or placebo for a period of 24 weeks. Effects on NPS were assessed using the NPI, the state sub‐score of the State‐Trait Anxiety Inventory and the Geriatric Depression Scale. Further outcome measures were the Trail‐Making Test (A/B) for cognition and global ratings of change. Statistical analyses followed the intention‐to‐treat principle. Results The NPI composite score decreased by 7.0 ± 4.5 (mean, standard deviation) points in the EGb 761‐treated group and by 5.5 ± 5.2 in the placebo group (p = 0.001). Improvement by at least 4 points was found in 78.8% of patients treated with EGb 761 and in 55.7% of those receiving placebo (p = 0.002). Superiority of EGb 761 over placebo (p 
ISSN:0885-6230
1099-1166
DOI:10.1002/gps.4103